Which Biotech ETF Is a Better Buy: Concentrated Bet or Broad Basket?

Invesco Nasdaq Biotechnology ETF (IBBQ) emerges as the better choice over VanEck Biotech ETF (BBH) for most investors. IBBQ offers broader diversification with 251 holdings, lower fees (0.19% vs 0.35%), higher dividend yield (0.8% vs 0.4%), and superior 5-year returns ($1,338 vs $1,061 on $1,000 invested). While BBH's concentrated 25-stock portfolio provides focused exposure to biotech leaders, it carries higher single-company risk without compensating benefits.

08/22/2026, 7:05 AM • The Motley Fool

IBBQ vs. PBE: Which Biotech ETF Is the Better Buy?

The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.

08/21/2026, 7:02 AM • The Motley Fool

Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Vertex Pharmaceuticals strengthens its dominant position in the cystic fibrosis market after competitor Sionna Therapeutics failed a clinical trial for its CF drug candidate. With continued CF portfolio improvements, patent exclusivity until the late 2030s, and promising newer medicines like Casgevy for rare blood diseases and Journavx for pain management, Wall Street remains bullish on Vertex's growth prospects.

08/20/2026, 3:30 PM • The Motley Fool

Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?

The Invesco Pharmaceuticals ETF (PJP) offers concentrated exposure to 29 pharma giants with better historical returns and lower volatility, while the Invesco Nasdaq Biotechnology ETF (IBBQ) provides broader diversification across 251 holdings at a lower expense ratio of 0.19% versus 0.57%. Despite IBBQ's cost advantage, PJP is recommended as the better buy due to its significantly larger asset base ($512.6M vs $81M), which addresses liquidity concerns.

08/19/2026, 7:15 AM • The Motley Fool

State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026?

State Street's XLV healthcare ETF offers broader exposure with lower costs (0.08% expense ratio) and higher dividend yield (1.6%), delivering 30% more growth over five years with lower volatility. VanEck's BBH biotech ETF provides concentrated exposure to 25 biotech stocks with higher recent returns but greater risk, making XLV the better choice for long-term investors seeking defensive characteristics.

08/05/2026, 3:02 PM • The Motley Fool

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy?

XLV, a broad healthcare ETF, offers lower costs (0.08% expense ratio) and higher dividend yield (1.60%) with more stability, while IBBQ, a concentrated biotech ETF, delivered stronger one-year returns (45.52% vs 26.79%) but with significantly higher volatility and drawdown risk. The choice depends on investor risk tolerance and investment objectives.

08/01/2026, 5:11 PM • The Motley Fool

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

Following Vertex Pharmaceuticals' $10 billion acquisition of Crinetics, Viking Therapeutics emerges as a potential takeover target due to its promising weight-loss drug pipeline, particularly VK2735 in phase 3 trials. The anti-obesity market is projected to reach $190 billion by 2035, making it attractive for pharmaceutical giants seeking to acquire proven candidates rather than develop from scratch. However, Viking's stock carries significant risk tied to upcoming phase 3 data readouts.

07/30/2026, 6:30 PM • The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy?

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

07/30/2026, 9:09 AM • The Motley Fool

Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees

Vanguard Health Care ETF (VHT) outperforms VanEck Biotech ETF (BBH) with lower fees (0.09% vs 0.35%), higher dividend yield (1.6% vs 0.5%), and superior 5-year returns ($1,278 vs $1,004 on $1,000 invested). VHT offers broad diversification across 411 healthcare holdings, while BBH provides concentrated biotech exposure with 25 stocks and higher volatility.

07/28/2026, 8:20 AM • The Motley Fool

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The article compares two healthcare-focused ETFs: iShares Global Healthcare ETF (IXJ) with 110 holdings offering global diversification and lower volatility, versus VanEck Biotech ETF (BBH) with 25 concentrated biotech positions delivering higher short-term returns but greater drawdown risk. IXJ is recommended for its superior long-term performance, geographic diversity, and stability despite BBH's impressive 30.8% one-year return.

07/23/2026, 3:30 PM • The Motley Fool

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Cyllene Therapeutics announced the appointment of Alyssa Levin to its Board of Directors as Audit Committee Chair, along with two key executive hires: Clara Cambon-Thiebaud as VP of Regulatory Affairs and Céline Breda as VP of Chemistry, Manufacturing and Controls. These appointments strengthen the company's leadership as it advances its lead candidate EG110A toward late-stage clinical development for neurogenic bladder-related incontinence.

07/23/2026, 1:30 AM • GlobeNewswire

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its cystic fibrosis focus into endocrine disease treatments. The deal could add up to $5 billion in annual revenue through approved drug Palsonify and pipeline candidate Atumelnant. While Vertex's stock initially fell post-announcement, the author suggests it could be a solid long-term buy given management's track record and enhanced growth prospects, despite the 29x trailing earnings valuation.

07/13/2026, 2:27 PM • The Motley Fool

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

07/12/2026, 3:30 PM • The Motley Fool

Why This Pharmaceutical Stock Jumped Close to 100% This Week

Crinetics Pharmaceuticals stock surged 98% this week following Vertex Pharmaceuticals' announcement of a $10 billion acquisition deal. Crinetics, which recently had its first FDA-approved drug (Palsonify) for acromegaly treatment, is now trading just below the $85 per share acquisition price. The deal allows Vertex to diversify beyond its cystic fibrosis focus into rare diseases, with combined assets projected to generate $5 billion in annual revenue.

07/10/2026, 3:02 PM • The Motley Fool

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals announced a $10 billion acquisition of Crinetics Pharmaceuticals to expand beyond its dominant cystic fibrosis portfolio into rare endocrine disorders. The deal provides access to Palsonify for acromegaly and a pipeline asset for congenital adrenal hyperplasia, potentially adding $5 billion in peak annual revenue. While the price is fair and strategically sound, results aren't expected until 2029, making it a long-term growth play for the biotech company.

07/10/2026, 4:05 AM • The Motley Fool